Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors
2005 ◽
Vol 58
(1)
◽
pp. 107-116
◽
2004 ◽
Vol 10
(7)
◽
pp. 2222-2230
◽